Apollomics Reports First Half 2023 Financial Results and : v

Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half...

Related Keywords

Beijing , China , United States , Kunpeng , Guangdong , Guo Liang Yu , Peter Vozzo , Sean Leous , Exchange Commission , Maxpro Capital Acquisition Corp , Nasdaq , Securities Exchange , Us National Cancer Institute , Apollomics Inc , China National Medical Products Administration , Chief Executive Officer , Drug Administration , Beijing Pearl , Breakthrough Therapy , Cancer Institute , Maxpro Capital Acquisition , Apollomic Class , Nasdaq Capital Market , Results Conference , Securities Act , Securities Exchange Act , Annual Report , Registration Statement , Nasdaq Aplm ,